In a Friday research note, he cut his rating on the stock to Hold from Buy and withdrew his previous $380 target for the ...
Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback